Surrogate antigens as targets for proteome-wide binder selection

New Biotechnology

Volumn 28, Issue 4, 2011, Pages 302-311

  Gustavsson, Elin ^a   Ek, Sara ^a   Steen, Johanna ^b   Kristensson, Malin ^a   Älgenäs, Cajsa ^b   Uhlén, Mathias ^b   Wingren, Christer ^a   Ottosson, Jenny ^b   Hober, Sophia ^b   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY REAGENTS; CHARACTERISATION; DISEASE BIOMARKER; FULL-LENGTH PROTEINS; HIGH THROUGHPUT; HUMAN PROTEINS; HUMAN PROTEOME; HYBRIDOMA TECHNOLOGY; IMMUNOHISTOCHEMISTRY; PHAGE DISPLAY; PHAGE SELECTION; PROOF OF PRINCIPLES; PROTEIN MICROARRAY; WESTERN BLOTS;

ANTIBODIES; ANTIGENS;

BINDERS;

ANTIGEN; EPITOPE; PROTEIN EPITOPE SIGNATURE TAG; PROTEOME; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MICROARRAY; WESTERN BLOTTING;

ANTIGENS; BINDING SITES; BIOLOGICAL MARKERS; IMMUNOASSAY; PROTEIN BINDING; PROTEOME;

EID: 79958056952     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2010.12.005     Document Type: Article

References (31)

1. Gloriam D.E., et al. A community standard format for the representation of protein affinity reagents. Mol. Cell. Proteomics 2010, 9:1-10.
2. Stoevesandt O., Taussig M.J. Affinity reagent resources for human proteome detection: initiatives and perspectives. Proteomics 2007, 7:2738-2750.
3. Hammarstrom M., et al. Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli. Protein Sci. 2002, 11:313-321.
4. Persson A., et al. A human protein atlas based on antibody proteomics. Curr. Opin. Mol. Ther. 2006, 8:185-190.
5. Saviranta P., Kallioniemi O. Human Protein Atlas charts a diverse terrain. Trends Biotechnol. 2006, 24:195-197.
6. Uhlen M., et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 2005, 4:1920-1932.
7. Schofield D.J., et al. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 2007, 8:R254.
8. Uhlen M., Hober S. Generation and validation of affinity reagents on a proteome-wide level. J. Mol. Recognit. 2009, 22:57-64.
9. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
10. Winter G., et al. Making antibodies by phage display technology. Annu. Rev. Immunol. 1994, 12:433-455.
11. Liu B., et al. Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol. 2002, 315:1063-1073.
12. Mersmann M., et al. Towards proteome scale antibody selections using phage display. Nat. Biotechnol. 2010, 27:118-128.
13. Konthur Z., et al. Perspectives for systematic in vitro antibody generation. Gene 2005, 364:19-29.
14. Agaton C., et al. Affinity proteomics for systematic protein profiling of chromosome 21 gene products in human tissues. Mol. Cell. Proteomics 2003, 2:405-414.
15. Ek S., et al. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. Mol. Cell. Proteomics 2006, 5:1072-1081.
16. Stenvall M., et al. High-throughput solubility assay for purified recombinant protein immunogens. Biochim. Biophys. Acta 2005, 1752:6-10.
17. Soderlind E., et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat. Biotechnol. 2000, 18:852-856.
18. Jirholt P., et al. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene 1998, 215:471-476.
19. Hallborn J., Carlsson R. Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques 2002, Suppl.:30-37.
20. Kampf C., et al. Antibody-based tissue profiling as a tool for clinical proteomics. Clin. Proteomics 2004, 1:285-299.
21. Wingren C., et al. Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 2007, 7:3055-3065.
22. Ingvarsson J., et al. Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J. Proteome Res. 2007, 6:3527-3536.
23. Carlsson S., et al. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - results from a prospective, population-based, randomised study. Eur. J. Cancer 2007, 43:2109-2116.
24. Berglund L., et al. A whole-genome bioinformatics approach to selection of antigens for systematic antibody generation. Proteomics 2008, 8:2832-2839.
25. Carlsson A., et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 2008, 44:472-480.
26. Maguire D., et al. Assaying ATP synthase rotor activity. Adv. Exp. Med. Biol. 2006, 578:67-72.
27. Ohara R., et al. Antibodies for proteomic research: comparison of traditional immunization with recombinant antibody technology. Proteomics 2006, 6:2638-2646.
28. Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 2006, 5:310-320.
29. Wingren C., Borrebaeck C.A. Antibody microarrays: current status and key technological advances. OMICS 2006, 10:411-427.
30. Zhu H., Snyder M. Protein chip technology. Curr. Opin. Chem. Biol. 2003, 7:55-63.
31. Anderson N.L., et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3:311-326.